Skip to Main Content

Paper Details

Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Leukemia
3
2022
Author NameAffiliation
Prasath PararajalingamSimon Fraser University
Ryan D MorinSimon Fraser University
David W Scott
  • 1 - 3

Datasets

Release 1.2